Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21468838 | 1.00 | HRH1 (1.00) | HRH1SLC6A2SLC6A3SLC6A4HTR1A | |
| Hydrochloric Acid SCHEMBL4443248 | 0.98 | HRH1 (0.96) | HRH1SLC6A2SLC6A3SLC6A4HTR1A | |
| Hydrochloric Acid SCHEMBL1237796 | 0.98 | HRH1 (0.96) | HRH1SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL29735458 | 0.92 | HRH1 (0.85) | HRH1SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL4324122 | 0.92 | HRH1 (0.85) | HRH1SLC6A2SLC6A3SLC6A4HTR1A | |
| Hydrochloric Acid SCHEMBL4321902 | 0.91 | HRH1 (0.82) | HRH1SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL5204218 | 0.88 | HRH1 (0.79) | HRH1SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL14828522 | 0.88 | HRH1 (0.78) | HRH1SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL226349 | 0.88 | HRH1 (0.78) | HRH1SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL2523551 | 0.88 | HRH1 (0.78) | HRH1SLC6A2SLC6A3SLC6A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 521 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118878508-A | DC-Rhoin derivative, preparation method and application thereof | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 2024-11-01 | — | — | CN | claimed |
| CN-118561742-A | Rupestonic acid amide derivative containing nitrogen heterocycle, and preparation method and application thereof | 中国科学院新疆理化技术研究所 | 2024-08-30 | — | — | CN | claimed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | claimed |
| EP-4058145-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| WO-2021094974-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | claimed |
| EP-3821947-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | SRX CARDIO, LLC (US) | 2018-07-31 | — | — | US | claimed |
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2017-08-31 | — | — | US | claimed |
| EP-3182971-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX Cardio, LLC (US) | 2017-06-28 | — | — | EP | claimed |
| WO-2016029037-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | SRX CARDIO, LLC (US) | 2016-02-25 | — | — | WO | claimed |
| EP-2179988-A1 | Producing (N-heterocyclic) aryl ethers | Saltigo GmbH (DE) | 2010-04-28 | — | — | EP | claimed |
| EP-0644878-B1 | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2001-09-12 | — | — | EP | claimed |
| US-5712272-A | TREATMENT OF NEUROLOGICAL DISORDERS WITH BENZ(B)AZEPINE COMPOUNDS | ZENECA LIMITED (GB) | 1998-01-27 | — | — | US | claimed |
| US-5708168-A | FOR TREATING OR PREVENTING NEURONAL LOSS | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1998-01-13 | — | — | US | claimed |
| US-5654295-A | NEUROLOGICAL DISORDERS; BENZ(B0AZEPINE COMPOUNDS | ZENECA LIMITED (GB) | 1997-08-05 | — | — | US | claimed |
| US-5492905-A | NERVOUS SYSTEM DISORDERS | ZENECA LIMITED (GB) | 1996-02-20 | — | — | US | claimed |
| EP-0644878-A1 | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS | ZENECA LIMITED (GB) | 1995-03-29 | — | — | EP | claimed |
| WO-1993025534-A1 | 2,5-DIOXO-2,5-DIHYDRO-1H-BENZ[b]AZEPINES AS NMDA RECEPTOR ANTAGONISTS | ZENECA LIMITED (GB) | 1993-12-23 | — | — | WO | claimed |
| EP-0023706-B1 | 4-PHENOXY PIPERIDINES, PROCESS FOR THEIR PREPARATION, THEIR USE AND MEDICAMENTS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1983-03-02 | — | — | EP | claimed |
| EP-0023706-A1 | 4-Phenoxy piperidines, process for their preparation, their use and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1981-02-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170246196-A1 | COMPOSITION AND METHODS OF USE OF SMALL MOLECULES AS BINDING LIGANDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9(PCSK9) PROTEIN ACTIVITY | PCSK9, LDLR, PCSK7 | HRH1 3794/4885SLC6A2 4825/4885SLC6A3 4844/4885 |
| US-10034892-B2 | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity | PCSK9, LDLR, PCSK7 | HRH1 3794/4885SLC6A2 4825/4885SLC6A3 4844/4885 |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | HRH1 517/4885SLC6A2 1153/4885SLC6A3 1191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.